Hong Kong Winhealth Pharma Group is a China-based, global innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The Group's Asia Pacific headquarter is located in Hong Kong, with operating hubs in Hangzhou, Shanghai, Beijing and Guangzhou. The company owns China's first rare disease managed access platform in Bo'ao, Hainan. The company also has representative offices in Japan, Singapore and Europe.
The Group has built a unique and diversified portfolio covering numerous innovative rare disease and specialty products at commercial and late clinical stages. It also makes constant efforts in introducing more innovative therapies from around the world.
Winhealth also has a strategic stake in the Cumberland Emerging Technologies (CET) program in the United States and has established an incubator in cooperation with the University of Tokyo Hospital in Japan, adopt global cutting-edge innovative technologies and products in the medical field, as well as enhance the communication and collaboration with relevant medical schools and research institutes all around the world. Winhealth always adheres to the patient-centered philosophy to contribute to the progress of global health cause and improvement of the quality of human life.